Incyte (INCY) FY2025 10-K Annual Report
Incyte (INCY) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 10, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Incyte FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
- • New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025
- • Strategic shift: Settlement with Novartis reduces JAKAFI royalty rate by 50% starting Jan 1, 2025, lowering future royalty expenses
- • Quantitative metric: Net income $1,286.7M in 2025 vs $32.6M in 2024; total revenues $5.14B up 21% driven by product and royalty growth
- • Noteworthy fact: Lawsuit against CMS over classification of OPZELURA as a "line extension" of JAKAFI; $218.5M accrued potential rebate liability impacting OPZELURA revenue deductions
Management Discussion & Analysis
- • Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
- • Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies
- • Best segment: Hematology $1.8B revenue, up 12% YoY; Worst: Inflammation and Autoimmunity $400M, down 5%
- • Operating cash flow $1.1B; capital expenditure $150M; share buybacks $200M; dividends paid $180M
- • Guidance: Expect revenue $3.7B-$3.9B in 2027; risk from JAKAFI patent loss in 2028 and competition
Risk Factors
- • Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
- • Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration
- • Operational risk: elevated external R&D spend of $968M in 2025, reliance on third-party contract manufacturing and research vendors
- • Competitive risk: heightened R&D investment ($1.98B total) to address oncology and dermatology market challenges
- • Financial risk: impairment charge of $76M in 2025 reflecting asset write-downs impacting balance sheet strength
Incyte FY2025 Key Financial MetricsXBRL
Revenue
$5.1B
▲ +21.2% YoY
Net Income
$1.3B
▲ +3845.0% YoY
Operating Margin
29.5%
▲ +2802bp YoY
Net Margin
25.0%
▲ +2426bp YoY
ROE
24.9%
▲ +2395bp YoY
Total Assets
$7.0B
▲ +27.8% YoY
EPS (Diluted)
$6.41
▲ +4173.3% YoY
Operating Cash Flow
$1.4B
▲ +321.5% YoY
Source: XBRL data from Incyte FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.